← All candidates
Two insider buys in the last year — $110.3K in all.
70 filings on record.
CAICaris Life Sciences, Inc.
NasdaqGS · Healthcare · $7.97B
$28.21
-1.02% · Sep 16
Two insider buys in the last year — $110.3K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys● 5 sells◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$7.97B
Float
134.9M
48% public
Short % float
Pro
Price / profit
3.0
Price / future profit
75.1
Price / sales
8.1
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
See Remarks
Brille Brian J
Bought $630.0K on Jun 20 — 30,000 sh @ $21.00, held direct, 19% of their stake.
0 of 1 position beat the S&P
See Remarks
Denton John Russel
Bought $157.5K on Jun 20 — 7,500 sh @ $21.00, held direct, 6.1% of their stake.
0 of 1 position beat the S&P
President
Spetzler David Baxley
Bought $9.5K on Nov 7 — 400 sh @ $23.85, held direct, 0.1% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
65 more transactions on Pro →Context
Wall St
$28.00 avg target
-0.7% vs today · 13 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q2 '26$0.00 act−$0.01
Q1 '26$0.00 act+$0.02
Q4 '25$0.28 act+$0.18
Q3 '25$0.08 act+$0.22
Coverage
Could Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update?Simply Wall St. · 1w agoCaris Life Sciences (CAI) Will Present Seven Studies At A Global Lung ConferenceSimply Wall St. · 1w agoWhat’s Next For Caris Life Sciences (CAI) After 21% Jump?Insider Monkey · 08-07Caris Life Sciences, Inc. Q2 2026 Earnings Call SummaryMoby · 08-06
The file stays open
70 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice